| 曾宪辉，麦瑞林，周衍国，黄敏旋，杨志强，谢锦智.沙库巴曲缬沙坦治疗缺血性心肌病患者的疗效及对内皮功能的调节机制[J].实用中西医结合临床,2021,21(15):6-7,56 |
| 沙库巴曲缬沙坦治疗缺血性心肌病患者的疗效及对内皮功能的调节机制 |
| Therapeutic Effect of Sacubitril/Valsartan on Patients with Ischemic Cardiomyopathy and Its Regulatory Mechanism on Endothelial Function |
| |
| DOI： |
| 中文关键词: 广东省东莞市企石医院内二科 |
| 英文关键词: Ischemic cardiomyopathy Sacubitril /valsartan Therapeutic effect Endothelial function |
| 基金项目: |
|
| 摘要点击次数: 444 |
| 全文下载次数: 208 |
| 中文摘要: |
| 目的：探讨沙库巴曲缬沙坦治疗缺血性心肌病患者的疗效及对内皮功能的调节机制。方法：将2019年6月~2020年12月就诊的70例缺血性心肌病患者随机分为两组，各35例。对照组给予常规治疗，观察组在常规治疗基础上给予沙库巴曲缬沙坦治疗。治疗12周后，比较两组总有效率、6 min步行实验（6MWT）、肱动脉血流介导的内皮依赖性舒张功能（FMD）、颈动脉内膜中层厚度（CIMT）、B型尿钠肽（BNP）及血管内皮功能相关指标水平，同时对比不良反应发生情况。结果：观察组总有效率为97.14%，高于对照组的77.14%（P＜0.05）；治疗后观察组BNP、血管内皮素（ET-1）水平低于对照组，而6MWT、一氧化氮（NO）水平则高于对照组（P＜0.05）；治疗后观察组FMD明显高于对照组，而CIMT明显低于对照组（P＜0.05）；不良反应方面，观察组总发生率为5.71%，远低于对照组的25.71%（P＜0.05）。结论：沙库巴曲缬沙坦可提高缺血性心肌病患者的临床疗效，降低不良反应发生率，并可通过调节内皮功能改善疾病预后。 |
| 英文摘要: |
| :Objective: To investigate the therapeutic effect of sacubitril/valsartan on patients with ischemic cardiomyopathy and the regulation mechanism of endothelial function. Methods: 70 patients with ischemic cardiomyopathy who were treated from June 2019 to December 2020 were randomly divided into control group and observation groups, with 35 cases in each group. The control group were given the conventional treatment, the observation group was treated with sacubitril/valsartan on the basis of conventional treatment. After 12 weeks of treatment, the effective rate, 6 min walking test (6MWT), brachial artery blood flow mediated endothelium-dependent relaxation function (FMD), carotid intima-media thickness (CIMT) , B-type natriuretic peptide (BNP) and vascular endothelium function were compared, while comparing adverse reactions. Results: The total effective rate of the observation group was 97.14%, which was higher than 77.14% of the control group (P＜0.05); after treatment, the BNP and vascular endothelin (ET-1) levels of the observation group were lower than those of the control group, while 6MWT and nitric oxide(NO) level were higher than those of the control group (P＜0.05); FMD of the observation group was significantly higher than that of the control group, while CIMT was significantly lower than that of the control group (P＜0.05); the total incidence of adverse reactions in the observation group was 5.71%, which was much lower than 25.71% in the control group (P＜0.05). Conclusion: Sacubitril/valsartan can improve the clinical efficacy of patients with ischemic cardiomyopathy, reduce the incidence of adverse reactions, and improve the prognosis of the disease by regulating endothelial function. |
|
查看全文
查看/发表评论 下载PDF阅读器 |
| 关闭 |
|
|
|
